CRBP
Corbus Pharmaceuticals Holdings, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
10.15
▲ 0.31 (3.15%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
9.85
Prev close
9.84
Day high
10.42
Day low
9.90
Volume
604.01K
Market cap
$200.76M
P/E (TTM)
—
52W range
7.12 – 20.56
Insider net activity
Net shares
+114.90K
Net buying
Buy transactions
10
159.23K shares
Sell transactions
6
44.34K shares
Net transactions
+16
Buys less sells
Sell : buy shares
0.3 : 1
Mixed
Insider-held shares
231.51K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 14, 26 | NICACIO LEONARDO VIANA M.D. Officer |
STOCK | 58.33K | $0 | Direct |
| Aug 11, 26 | SAXENA NISHANT C Officer |
BUY | 2.60K | $25.04K | Direct |
| Aug 7, 26 | MORAN SEAN F Chief Financial Officer |
SELL | 12.00K | $120.97K | Direct |
| Aug 7, 26 | COHEN YUVAL Chief Executive Officer |
SELL | 17.00K | $171.40K | Direct |
| Jun 10, 26 | KUNG WINSTON Director |
SELL | 2.03K | $16.03K | Direct |
| Jun 10, 26 | JENKINS JOHN KENNETH M.D. Director |
SELL | 4.80K | $37.99K | Direct |
| Jun 10, 26 | ALTMEYER ANNE Director |
SELL | 2.41K | $19.09K | Direct |
| Jun 3, 26 | SAXENA NISHANT C Officer |
BUY | 13.50K | $101.22K | Direct |
| May 21, 26 | SAXENA NISHANT C Officer |
STOCK | 58.30K | $0 | Direct |
| May 19, 26 | KUNG WINSTON Director |
STOCK | 3.80K | $0 | Direct |
| May 19, 26 | JENKINS JOHN KENNETH M.D. Director |
STOCK | 3.80K | $0 | Direct |
| May 19, 26 | JACQUES RACHELLE SUZANNE Director |
STOCK | 3.80K | $0 | Direct |
| May 19, 26 | ALTMEYER ANNE Director |
STOCK | 3.80K | $0 | Direct |
| May 19, 26 | BEN YONG Director |
STOCK | 3.80K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BEN YONG |
Director | 11.38K | Stock Award(Grant) |
COHEN YUVAL |
Chief Executive Officer | 157.32K | Sale |
CORMORANT ASSET MANAGEMENT ,L.P |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
HODGSON IAN |
Chief Operating Officer | 51.08K | Sale |
JACQUES RACHELLE SUZANNE |
Director | 11.38K | Stock Award(Grant) |
KUNG WINSTON |
Director | 12.14K | Sale |
MORAN SEAN F |
Chief Financial Officer | 84.69K | Sale |
NICACIO LEONARDO VIANA M.D. |
Officer | 58.33K | Stock Award(Grant) |
SAXENA NISHANT C |
Officer | 77.90K | Purchase |
SMETHURST DOMINIC |
Officer | 89.79K | Sale |
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
2.25
Put-heavy session
Put / call open interest
0.35
Positioning, not flow
Max pain
10.00
-3.7% from spot
ATM implied vol
118.4%
Nearest strike to spot
Skew (10% OTM)
+22.0%
Puts bid over calls
Call volume
159
Contracts, this expiry
Put volume
358
Contracts, this expiry
Heaviest call OI
12.50
2.24K contracts
Heaviest put OI
10.00
1.21K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
+2.87%
+4.2%
1M
+11.37%
+7.6%
3M
-9.82%
-12.9%
6M
+39.89%
+28.8%
YTD
+27.52%
+15.2%
1Y
+12.58%
-7.4%
3Y
+68.23%
-5.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$200.76M
Enterprise value$87.09M
Revenue (TTM)—
Gross profit$-90.26M
EBITDA$-106.68M
Net income$-101.90M
EPS (TTM)$-6.11
Free cash flow$-49.62M
Total cash$117.94M
Total debt$4.26M
Book value / share$5.48
Shares outstanding19.34M
Float15.16M
Short % of float14.17%
Dividend yield—
Beta (5Y)2.62
Short interest
Shares short
2.30M
Prior 1.95M
Change vs prior
+18.2%
Shorts adding
% of float
14.17%
Elevated
% of shares out
12.32%
Against total outstanding
Days to cover
7.4
Crowded exit
Float
15.16M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.88
PEG ratio—
Price / sales—
Price / book1.90
EV / revenue—
EV / EBITDA-0.82
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-95.58%
Return on assets-53.00%
Debt / equity4.17
Current ratio5.71
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $70.09M | $32.22M | $31.17M | $16.14M | +117.5% |
| Selling, general & admin | $15.21M | $16.50M | $13.91M | $18.70M | -7.8% |
| Total operating expense | $85.31M | $48.72M | $45.08M | $34.84M | +75.1% |
| Operating income | -$85.31M | -$48.72M | -$45.08M | -$34.84M | -75.1% |
| Net interest income | $5.53M | $4.44M | -$2.22M | -$2.13M | +24.6% |
| Pre-tax income | -$78.54M | -$40.21M | -$44.60M | -$42.35M | -95.3% |
| Net income | -$78.54M | -$40.21M | -$44.60M | -$42.35M | -95.3% |
| Net income to common | -$78.54M | -$40.21M | -$44.60M | -$42.35M | -95.3% |
| Basic EPS | -5.90 | -3.68 | -10.31 | -10.15 | -60.3% |
| Diluted EPS | -5.90 | -3.68 | -10.31 | -10.15 | -60.3% |
| EBIT | -$78.54M | -$38.34M | -$40.75M | -$34.84M | -104.9% |
| EBITDA | -$78.30M | -$37.75M | -$40.10M | -$34.07M | -107.4% |
| Basic shares | 13.32M | 10.92M | 4.33M | 4.17M | +22.0% |
| Diluted shares | 13.32M | 10.92M | 4.33M | 4.17M | +22.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $28.49M | $17.20M | $13.72M | $17.00M | — | +65.7% |
| Cash & short-term investments | $163.27M | $149.06M | $20.91M | $59.20M | — | +9.5% |
| Total current assets | $166.95M | $152.98M | $23.55M | $60.18M | — | +9.1% |
| Property, plant & equipment | $1.24M | $2.52M | $4.04M | $5.50M | — | -50.7% |
| Total assets | $168.19M | $155.88M | $28.27M | $66.31M | — | +7.9% |
| Total current liabilities | $20.69M | $11.82M | $31.89M | $12.64M | — | +75.1% |
| Current debt | — | — | $16.21M | $3.15M | $3.86M | — |
| Long-term debt | — | — | — | $15.98M | $15.64M | — |
| Total debt | $1.63M | $3.24M | $20.89M | $25.09M | — | -49.6% |
| Total liabilities | $20.69M | $13.45M | $35.18M | $33.32M | — | +53.8% |
| Retained earnings | -$555.43M | -$476.89M | -$436.68M | -$392.08M | — | -16.5% |
| Shareholder equity | $147.50M | $142.43M | -$6.91M | $32.99M | — | +3.6% |
| Working capital | $146.26M | $141.16M | -$8.35M | $47.54M | — | +3.6% |
| Net tangible assets | $147.50M | $142.43M | -$6.91M | $32.99M | — | +3.6% |
| Shares issued | 17.61M | 12.18M | 4.42M | 4.17M | — | +44.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$78.54M | -$40.21M | -$44.60M | -$42.35M | — | -95.3% |
| Depreciation & amortisation | $233.00K | $588.00K | $641.00K | $763.00K | — | -60.4% |
| Stock-based compensation | $6.29M | $6.14M | $3.47M | $5.72M | — | +2.3% |
| Change in working capital | $9.12M | -$5.58M | $4.09M | -$3.30M | — | +263.6% |
| Operating cash flow | -$64.49M | -$41.79M | -$36.10M | -$37.54M | — | -54.3% |
| Capital expenditure | -$7.00K | — | — | -$13.45K | -$54.17K | — |
| Investing cash flow | -$1.64M | -$121.31M | $35.64M | $30.07M | — | +98.6% |
| Financing cash flow | $77.43M | $166.58M | -$2.82M | -$533.62K | — | -53.5% |
| Free cash flow | -$64.50M | -$41.79M | -$36.10M | -$37.56M | — | -54.3% |
| End cash position | $29.16M | $17.87M | $14.39M | $17.67M | — | +63.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $31.18M | $19.82M | $18.41M | $20.86M | $15.19M | +57.3% |
| Selling, general & admin | $5.01M | $4.49M | $3.56M | $3.56M | $3.96M | +11.8% |
| Total operating expense | $36.19M | $24.30M | $21.97M | $24.42M | $19.15M | +48.9% |
| Operating income | -$36.19M | -$24.30M | -$21.97M | -$24.42M | -$19.15M | -48.9% |
| Net interest income | $1.16M | $1.40M | $1.41M | $1.13M | $1.31M | -17.0% |
| Pre-tax income | -$35.04M | -$22.97M | -$20.55M | -$23.34M | -$17.66M | -52.5% |
| Net income | -$35.04M | -$22.97M | -$20.55M | -$23.34M | -$17.66M | -52.5% |
| Net income to common | -$35.04M | -$22.97M | -$20.55M | -$23.34M | -$17.66M | -52.5% |
| Basic EPS | -1.81 | -1.23 | -1.25 | -1.90 | -1.44 | -47.2% |
| Diluted EPS | -1.81 | -1.23 | -1.25 | -1.90 | -1.44 | -47.2% |
| EBIT | -$36.19M | -$24.30M | -$20.55M | -$23.34M | -$19.15M | -48.9% |
| EBITDA | -$36.14M | -$24.25M | -$20.51M | -$23.29M | -$19.10M | -49.0% |
| Basic shares | 19.41M | 18.71M | 16.48M | 12.31M | 12.24M | +3.7% |
| Diluted shares | 19.41M | 18.71M | 16.48M | 12.31M | 12.24M | +3.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $23.37M | $25.66M | $28.49M | $26.98M | $20.04M | -8.9% |
| Cash & short-term investments | $117.94M | $138.22M | $163.27M | $103.98M | $116.59M | -14.7% |
| Total current assets | $122.75M | $143.57M | $166.95M | $107.57M | $122.83M | -14.5% |
| Property, plant & equipment | $3.85M | $914.00K | $1.24M | $1.56M | $1.88M | +321.2% |
| Total assets | $126.99M | $144.48M | $168.19M | $109.51M | $125.08M | -12.1% |
| Total current liabilities | $21.48M | $18.14M | $20.69M | $17.06M | $13.33M | +18.4% |
| Total debt | $4.26M | $1.21M | $1.63M | $2.05M | $2.46M | +253.9% |
| Total liabilities | $24.75M | $18.14M | $20.69M | $17.37M | $14.09M | +36.4% |
| Retained earnings | -$613.44M | -$578.40M | -$555.43M | -$534.88M | -$511.53M | -6.1% |
| Shareholder equity | $102.24M | $126.34M | $147.50M | $92.15M | $110.99M | -19.1% |
| Working capital | $101.27M | $125.43M | $146.26M | $90.51M | $109.49M | -19.3% |
| Net tangible assets | $102.24M | $126.34M | $147.50M | $92.15M | $110.99M | -19.1% |
| Shares issued | 17.74M | 17.74M | 17.61M | 12.53M | 12.25M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$35.04M | -$22.97M | -$20.55M | -$23.34M | -$17.66M | — | -52.5% |
| Depreciation & amortisation | $51.00K | $49.00K | $49.00K | $50.00K | $53.00K | — | +4.1% |
| Stock-based compensation | $1.81M | $1.92M | $1.43M | $1.58M | $1.56M | — | -5.7% |
| Change in working capital | $3.77M | -$4.30M | $3.83M | $6.16M | $122.00K | — | +187.6% |
| Operating cash flow | -$29.63M | -$25.57M | -$15.92M | -$15.55M | -$16.60M | — | -15.9% |
| Capital expenditure | -$6.00K | -$6.00K | — | — | — | — | 0.0% |
| Investing cash flow | $18.26M | $22.45M | -$57.15M | $19.64M | $17.74M | — | -18.7% |
| Financing cash flow | — | — | $74.58M | $2.85M | $0 | $0 | — |
| Free cash flow | -$29.63M | -$25.58M | -$15.93M | -$15.55M | -$16.60M | — | -15.9% |
| End cash position | $23.75M | $26.05M | $29.16M | $27.65M | $20.71M | — | -8.8% |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.24 | -1.81 | -46.3% |
| Mar 2026 | -1.22 | -1.23 | -0.8% |
| Dec 2025 | -1.58 | -1.25 | +20.7% |
| Sep 2025 | -1.71 | -1.90 | -11.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.21 | 10 | $1.11M | 0.0% |
| Next quarter | -1.32 | 10 | $0 | 0.0% |
| Current year | -5.43 | 10 | $1.11M | 0.0% |
| Next year | -5.51 | 9 | $2.40M | +116.0% |
Analyst targets & ownership
Mean target$34.53
High target$48.00
Low target$17.25
Implied upside240.15%
Analyst count10
ConsensusSTRONG BUY
Strong buy / Buy1 / 9
Hold0
Sell / Strong sell0 / 0
Held by insiders1.20%
Held by institutions73.36%
Institutions holding137
Price targets, consensus spread, insider and institutional ownership.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Aug 7, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 23, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Jun 17, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| May 27, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| May 26, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 22, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| May 13, 26 | Jefferies | MAINTAINED | Buy | Buy |
| May 13, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| May 13, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Apr 29, 26 | Guggenheim | INITIATED | — | Buy |
| Mar 10, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
Moving averages & technicals
SMA 10
9.97
+1.83% from price
SMA 20
9.63
+7.80% from price
SMA 50
9.14
+13.56% from price
SMA 100
9.45
+7.45% from price
SMA 200
9.27
+11.97% from price
EMA 12
9.93
+2.24% from price
EMA 26
9.63
+5.40% from price
EMA 50
9.41
+7.91% from price
RSI (14)
61.6
Neutral
MACD (12,26,9)
0.30
Hist 0.04
ATR (14)
0.55
5.31% of price
Realised vol 30D
48.9%
Annualised
Bollinger upper
10.62
20, 2σ
Bollinger lower
8.64
20, 2σ
50 / 200 cross
Death
9.14 vs 9.27
Trend bias
Above 200
+11.97%
Risk profile
Beta vs SPY
0.99
Less volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
48.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-61.9%
Peak to trough
Max drawdown 5Y
-94.6%
Peak to trough
ATR 14
0.55
5.31% of price
Beta (reported)
2.62
5Y monthly, from filing
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:30
Split dateFeb 14, 2023
SEC filings
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-06
Offering Registrations
S-8 · 2026-06-17
Offering Registrations
S-8 · 2026-05-29
Corporate Changes & Voting Matters
8-K · 2026-05-26
Corporate Changes & Voting Matters
8-K · 2026-05-21
Corporate Changes & Voting Matters
8-K · 2026-05-14
Periodic Financial Reports
10-Q · 2026-05-12
Headlines
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 5d ago
Mizuho Adjusts PT on Corbus Pharmaceuticals to $33 From $34, Keeps Outperform Rating
MT Newswires · 10d ago
Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $48 From $52, Maintains Outperform Rating
MT Newswires · 15d ago
Corbus Pharmaceuticals: Q2 Earnings Snapshot
Associated Press · 16d ago
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
GlobeNewswire · 16d ago
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
GlobeNewswire · 18d ago
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer
GlobeNewswire · 25d ago
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
GlobeNewswire · 47d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.